Gross profit of Innovent Biologics 2019-2022
In 2022, the gross profit of Chinese pharmaceutical firm Innovent Biologics Inc. amounted to 3.68 billion yuan, decreasing by around 3.7 percent from the year prior. The core products of Innovent Biologics include anti-tumor medicines and drugs treating metabolic disorders and autoimmune diseases.